Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Akero Therapeutics Inc (AKRO)

Akero Therapeutics Inc (AKRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,119,616
  • Shares Outstanding, K 37,571
  • Annual Sales, $ 0 K
  • Annual Income, $ -100,780 K
  • 60-Month Beta 0.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.32
Trade AKRO with:

Options Overview Details

View History
  • Implied Volatility 91.53% ( +18.18%)
  • Historical Volatility 261.07%
  • IV Percentile 70%
  • IV Rank 13.59%
  • IV High 331.71% on 09/02/22
  • IV Low 53.75% on 12/23/21
  • Put/Call Vol Ratio 2.10
  • Today's Volume 3,955
  • Volume Avg (30-Day) 4,624
  • Put/Call OI Ratio 1.88
  • Today's Open Interest 28,224
  • Open Int (30-Day) 23,965

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.79
  • Number of Estimates 4
  • High Estimate -0.70
  • Low Estimate -0.85
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -12.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.48 +225.06%
on 09/07/22
35.38 -3.76%
on 09/30/22
+21.69 (+175.49%)
since 08/30/22
3-Month
9.31 +265.74%
on 07/01/22
35.38 -3.76%
on 09/30/22
+24.60 (+260.32%)
since 06/30/22
52-Week
7.52 +352.79%
on 06/13/22
35.38 -3.76%
on 09/30/22
+11.70 (+52.35%)
since 09/30/21

Most Recent Stories

More News
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors

Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.

ALT : 12.77 (+1.19%)
ICPT : 13.95 (-14.99%)
ACER : 1.3900 (-0.71%)
AKRO : 34.05 (+14.26%)
Stocks Mixed As Fed Rate Hike Looms

September S&P 500 futures (ESU22) are moderately up +0.03% this morning after three major US benchmark indices bounced back during the regular session as an on-target inflation report mainly stopped the...

ESU22 : 3,871.24s (-0.79%)
APA : 34.19 (-2.17%)
RYTM : 24.50 (+2.64%)
IRNT : 0.6890 (-2.59%)
AKRO : 34.05 (+14.26%)
RIVN : 32.91 (+1.86%)
NEE : 78.41 (-1.95%)
FSR : 7.55 (-1.18%)
PANW : 163.79 (-1.08%)
ERIC : 5.74 (-0.17%)
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More

Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.

REGN : 688.87 (-0.43%)
BMY : 71.09 (-0.86%)
NVAX : 18.20 (-1.99%)
AMLX : 28.15 (-6.76%)
AKRO : 34.05 (+14.26%)
Akero Therapeutics (AKRO) Up on Positive Data from NASH Study

Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.

ICPT : 13.95 (-14.99%)
VKTX : 2.72 (-1.09%)
AKRO : 34.05 (+14.26%)
IMCR : 46.94 (+2.40%)
Stocks Mixed After U.S. CPI Shock Raises Fed Rate Risks

September S&P 500 futures (ESU22) are trending up +0.66% this morning after three major US benchmark indices veered sharply lower, marking their biggest single-day percentage declines since June 2020.

ESU22 : 3,871.24s (-0.79%)
ADTX : 3.39 (+0.30%)
SBUX : 84.26 (-2.67%)
AKRO : 34.05 (+14.26%)
NVDA : 121.39 (-0.66%)
PNT : 7.73 (-1.53%)
STX : 53.23 (-2.11%)
Akero Therapeutics (NASDAQ: AKRO) Squeezes Shorts After Stronger-then-Expected Results from Phase 2b HARMONY Study of EFX

Akero Therapeutics, Inc. (NASDAQ: AKRO) is engaged as a clinical-stage biotechnology company that is focused on the research and development

AKRO : 34.05 (+14.26%)
Why Akero Therapeutics Stock Is on Fire Today

The biotech's experimental NASH drug hit the mark in a key phase 2b trial.

AKRO : 34.05 (+14.26%)
Peloton's Shake-Up Continues, but This Tiny Stock Doubled Early Tuesday

As the connected fitness equipment maker keeps going through turmoil, good news helped lift a largely unknown company's share price.

COMP : 2.32 (-0.43%)
$DOWI : 28,725.51 (-1.71%)
$SPX : 3,585.62 (-1.51%)
$NASX : 10,575.62 (-1.51%)
PTON : 6.93 (-1.70%)
AKRO : 34.05 (+14.26%)
Akero Therapeutics (AKRO) Up on Positive NASH Study Data

Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.

PFE : 43.76 (-0.91%)
HTGC : 11.58 (+1.14%)
RYTM : 24.50 (+2.64%)
AKRO : 34.05 (+14.26%)
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing...

AKRO : 34.05 (+14.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which...

See More

Key Turning Points

3rd Resistance Point 42.07
2nd Resistance Point 38.72
1st Resistance Point 36.39
Last Price 34.05
1st Support Level 30.71
2nd Support Level 27.36
3rd Support Level 25.03

See More

52-Week High 35.38
Last Price 34.05
Fibonacci 61.8% 24.74
Fibonacci 50% 21.45
Fibonacci 38.2% 18.16
52-Week Low 7.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar